Welcome to issue 72 of Pharmafile, covering topics such as antimicrobial resistance, rare diseases and skin conditions


cover, antimicrobial resistance, rare diseases, skin conditions


Pharmafile

Somewhere over the redbow, you will find...

redbow consulting

Therapeutic Areas in Focus, infectious diseases, rare diseases, dermatology


Charting the course to 2022

The 2022 International Clinical Researcher of the Year competition is open for entry!

international clinical researcher of the year competition

Pharma Times

Pharmafile speaks to DeepDrug: DeepDrug tells Pharmafile about the development of new drugs for neglected and infectious diseases, including how AI can be used in the drug development process


Deep down inside: How AI is supporting new therapeutic combinations

Following a global survey on antimicrobial resistance, a global plan has been initiated by WHO, this article explores the further steps that can be taken in AMR planning


antimicrobial resistance, infectious diseases


Resisting change: The pathway to better AMR planning

Health data systems can be used to directly help patients engage with their care and build trust with their HCPs, this article explores these strategies, placing patient outcomes at the centre of care


A bold & ambitious plan: Harnessing data and improving health & care continuity for the next decade

Redbow explains their healthcare consultancy strategy and shares details about the company


Redbow Consulting Group

AI can help infectious diseases remain in the spotlight and help them gain interest from R&D investors, this article explains how


Delivering transformational data analysis for infectious disease drug discovery

PHARMAFILE SPEAKS TO The Brain Charity: The Brain Charity explain how they've been providing support to patients with rare diseases throughout the COVID-19 pandemic


PHARMA FILES PEAKS TO The Brain Charity, Neurology, rare diseases, COVID-19, charity, brain


Supporting rare neurological disease patients during COVID-19

Ipsen tells Pharmafile about the underestimated impacts of rare and ultra-rare diseases


rare diseases, ultra-rare diseases, diagnosis, challenges


Treatable, untreatable, undetermined: Overcoming rare disease

Pharmafile: Global Pharmaceutical Webinars

Rare and ultra-rare diseases impact a surprising amount of people, this article explores the field of rare diseases as well as the diagnostic journey many patients take


Rare disease and orphan medicines – Will gover nment policy change the paradigm?

Patients play an important but often forgotten role in drug development, this article considers the significance of patient experience while developing treatments


patient experience, rare diseases, treatments


Every number has a face: Are you valuing the patient voice?

A lack of research, funding and representation for rare diseases can lead to under diagnosis, this article looks to the future of rare disease treatments

rare diseases, genetic diseases, drug development


Not so rare diseases: The cumulative burden of underdiagnosis

Pharmafilespeaks to Allergy UK: Allergy UK explores the future of eczema diagnosis, treatment, and support


Pharmafilespeaks to Allergy UK, dermatology, eczema, charity, skin 


Scratching the surface of eczema care in the UK

PME: Pharmaceutical Market Europe: Make sure you always have access to your copy of PME!

PME 

Skin diseases have many impacts on patients' lives, AbbVie explores these impacts


‘Cumulative life course impairment’: The unforeseen burdens of severe eczema

Organon discusses the ways in which women's skin conditions can be managed


dermatology, skin conditions, women's health


Dermatologically speaking: Finding new treatments for women

FIDE discuss the need for communication between patients and their HCPs, specifically with virtual platforms in mind, and how this can improve dermatology care


dermatology, skin conditions, HCPs, COVID-19, digital health

Insight and oversight: Making the most of virtual platforms in dermatology

There have been significant advances in dermatological care, this article explores this as well as looking forward to what still needs to be done


dermatology, skin conditions, patient experience, pain 


“The pain keeps me awake at night. I can’t cope with this anymore”

The COVID-19 pandemic has been challenging service-wide for the NHS, but the pharma industry can support patients and the NHS going forward

dermatology, skin conditions, patient experience, NHS, COVID-19

Supporting dermatology and oncology services to build back better post-COVID-19

Samedan Ltd: Covering every stage of the supply chain

samedan, pharmaceutical, publishers, pharma 

SAMEDAN

ICON: Antimicrobial Resistance: How clinical research can combat an ensuing global crisis

Antimicrobial resistance

The rare disease spectrum

Approaching eczema in 2022

redbow consulting